Enliven Therapeutics (NASDAQ:ELVN) Shares Up 6.4% After Analyst Upgrade

Enliven Therapeutics, Inc. (NASDAQ:ELVN) traded up 6.4% on Tuesday after Wall Street Zen upgraded the stock from a sell rating to a hold rating. The stock traded as high as $40.94 and last traded at $42.1210. 20,392 shares changed hands during trading, a decline of 98% from the average session volume of 1,169,657 shares. The stock had previously closed at $39.59.

ELVN has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Monday, April 20th. Mizuho upped their price objective on Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday, March 25th. The Goldman Sachs Group raised their price objective on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a report on Friday. Finally, HC Wainwright boosted their target price on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $53.17.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 10,000 shares of the company’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $29.58, for a total value of $295,800.00. Following the sale, the chief financial officer owned 51,000 shares in the company, valued at approximately $1,508,580. The trade was a 16.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Richard A. Heyman sold 1,230 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total value of $32,201.40. Following the transaction, the director owned 22,647 shares of the company’s stock, valued at $592,898.46. This trade represents a 5.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 25.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ELVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Enliven Therapeutics by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after buying an additional 1,693 shares during the period. Goldman Sachs Group Inc. raised its stake in Enliven Therapeutics by 61.3% during the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock worth $4,167,000 after buying an additional 80,506 shares during the last quarter. Jane Street Group LLC acquired a new position in Enliven Therapeutics in the first quarter valued at $578,000. Legal & General Group Plc boosted its position in Enliven Therapeutics by 52.2% during the second quarter. Legal & General Group Plc now owns 32,225 shares of the company’s stock valued at $646,000 after acquiring an additional 11,058 shares during the last quarter. Finally, Quantbot Technologies LP boosted its position in Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after acquiring an additional 1,434 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

The stock has a fifty day simple moving average of $37.48 and a two-hundred day simple moving average of $27.59. The stock has a market capitalization of $2.62 billion, a price-to-earnings ratio of -25.76 and a beta of 0.32.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. Research analysts forecast that Enliven Therapeutics, Inc. will post -1.7 earnings per share for the current year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.